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PeroxisomeEthanolamine plasmalogens constitute a group of ether glycerophospholipids that, due to their unique biophys-
ical and biochemical properties, are essential components of mammalian cellular membranes. Their importance
is emphasized by the consequences of defects in plasmalogen biosynthesis, which in humans cause the fatal
disease rhizomelic chondrodysplasia punctata (RCDP). In the present lipidomic study, we used ﬁbroblasts
derived from RCDP patients, as well as brain tissue from plasmalogen-deﬁcient mice, to examine the compensa-
tory mechanisms of lipid homeostasis in response to plasmalogen deﬁciency. Our results show that phosphati-
dylethanolamine (PE), a diacyl glycerophospholipid, which like ethanolamine plasmalogens carries the head
group ethanolamine, is the main player in the adaptation to plasmalogen insufﬁciency. PE levels were tightly
adjusted to the amount of ethanolamine plasmalogens so that their combined levelswere kept constant. Similar-
ly, the total amount of polyunsaturated fatty acids (PUFAs) in ethanolamine phospholipids wasmaintained upon
plasmalogen deﬁciency. However, we found an increased incorporation of arachidonic acid at the expense of
docosahexaenoic acid in the PE fraction of plasmalogen-deﬁcient tissues. These data show that under conditions
of reduced plasmalogen levels, the amount of total ethanolamine phospholipids is preciselymaintained by a rise
in PE. At the same time, a shift in the ratio between ω-6 and ω-3 PUFAs occurs, which might have unfavorable,
long-term biological consequences. Therefore, our ﬁndings are not only of interest for RCDP but may have
more widespread implications also for other disease conditions, as for example Alzheimer's disease, that have
been associated with a decline in plasmalogens.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Introduction
The lipid composition of biological membranes is of great importance
for cellular functions. Its dynamic adaptation to speciﬁc requirements is aerone phosphate synthase; BA,
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. This is an open access article undercrucial feature of lipidmembranes inmammalian tissues. Themost abun-
dantmembrane lipids are phospholipids, which are typically amphipath-
ic and, thereby, make up the characteristic lipid bilayer structure of
biological membranes. Among the phospholipids forming the bilayer,
the major classes are the glycerophospholipids phosphatidylcholine
(PC), phosphatidylethanolamine (PE), phosphatidylserine (PS) and the
ether phospholipids (including plasmalogens), as well as sphingomyelin
(SM), a sphingolipid. Each of these is further subdivided into a variety of
distinct species based on their fatty acid chains. Eukaryotic cells are able
to ﬁne-tune the mixture of these lipids according to their biological task
[1]. Furthermore,membranes adapt to various environmental conditions,
like for example circadian rhythms or changes in temperature, by altering
their lipid composition [2,3]. The dynamic aspect of lipid membranes is
additionally underscored by the existence of membrane rafts (formerly
termed lipid rafts), small protein–lipid domains enriched in sphingolipids
and sterols, two other prevalent membrane lipid classes in addition to
glycerophospholipids. Membrane rafts assemble transiently and com-
partmentalize important biological functions like signal transduction [4].the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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that have an O-alkyl group at their sn-1 position, which distinguishes
them from the diacyl phospholipids. The most abundant subclass of
ether phospholipids are the plasmalogens, which account for almost
20% of the phospholipid mass in humans [5]. These compounds carry
a double bond adjacent to the ether bond, together forming a vinyl
ether bond, which is characteristic of plasmalogens (Fig. 1A). Other
ether phospholipids include plasmanyl phospholipids (containing a sat-
urated ether moiety at the sn-1 position), platelet-activating factor,
seminolipid, and, partly, the glycosylphosphatidylinositol (GPI) anchor
ofmembrane proteins. The biosynthesis of ether phospholipids requires
peroxisomes. In the lumen of these organelles, the concerted action of
the two enzymes glyceronephosphate acyltransferase (GNPAT; alterna-
tive name: dihydroxyacetone phosphate acyltransferase (DHAPAT,
DAPAT)) and alkylglycerone phosphate synthase (AGPS) generates
the characteristic ether bond. The remaining biosynthetic steps, includ-
ing the introduction of the vinyl double bond in case of plasmalogens,
are subsequently accomplished at the endoplasmic reticulum (ER).
The generation of the alkyl group at sn-1 depends on fatty alcohols
that are either derived from dietary intake or synthesized by the fatty
acyl-CoA reductases FAR1 or FAR2 [6]. Recently, FAR1, which preferably
accepts saturated or monounsaturated C16 or C18 acyl-CoA esters
as substrates, was suggested as the main reductase involved in
plasmalogen biosynthesis [7]. Accordingly, C16:0, C18:0 and C18:1 are
the major fatty alcohol species at the sn-1 position of plasmalogens.
The fatty acid composition at sn-2 strongly depends on the cell type.
In general, plasmalogens are enriched in polyunsaturated fatty acids
(PUFAs), a fact that is especially pronounced in neurons. In brain
whitematter, however,monounsaturated species prevail to ensuremy-
elin stability [8]. In most tissues, ethanolamine is the dominating head
group. Choline plasmalogens play an important role in cardiac tissue,
but represent a minor species in most other organs. Other head groups,
like serine or inositol, are extremely rare. Asmajor constituents of cellu-
lar membranes, plasmalogens shape membrane structure and dynam-
ics. They also have been shown to be enriched in membrane rafts [9].
Furthermore, in some cell types, the frequent occurrence of PUFAs in
the side chains of plasmalogens engages them as a storage depot for
these essential fatty acids [10,11]. Additional functions like anti-
oxidative action [12,13], stimulation of invariant natural killer T cells
[14], membrane fusion [15,16] or constriction [17] and in generating
lipid second messengers [18] have been proposed based on in vitro
ﬁndings and experiments in ether phospholipid-deﬁcient mouse
models [19–22]. However, the exact biological roles of these lipids and
the underlying molecular mechanisms are still enigmatic.
In humans, deﬁciency of ether phospholipids evokes rhizomelic
chondrodysplasia punctata (RCDP), a rare, autosomal recessive disorder
caused by mutations in the genes encoding the peroxisomal enzymesFig. 1. Structures of PlsEtn (A) and PE (B). R1 indicates the alkyl residues originating from
the primary alcohols C16:0, C18:1 or C18:0. R2, R3 and R4 can be various fatty acyl residues.GNPAT (RCDP type 2) and AGPS (RCDP type 3) or peroxin 7 (PEX7;
RCDP type 1), the receptor needed for peroxisomal import of AGPS
[23–27]. Affected individuals suffer from a variety of severe symptoms,
including growth and mental retardation, shortening of the proximal
long bones, epiphyseal stippling, cataracts and joint contractures. In its
severest form, RCDP is fatal during the ﬁrst months of life, predominantly
due to respiratory failure [28]. However, also less severe variants (“inter-
mediate phenotype”) of the disease have been described, where residual
plasmalogen biosynthesis slightly alleviates the symptoms [29–34]. Ether
phospholipid deﬁciency is also a key feature of peroxisome biogenesis
disorders, such as the Zellweger syndrome, in which peroxisomes cannot
be properly assembled [35]. Moreover, reduced plasmalogen levels have
also been observed in several more common disorders like Alzheimer's
disease [36–38], Parkinson's disease [39], Down syndrome [40], or schizo-
phrenia [41] and have been suggested to constitute a part of the patho-
logical mechanism during disease development.
Ethanolamine plasmalogens (PlsEtn, also called plasmenylethanol-
amines) and the diacyl glycerophospholipid PE (Fig. 1B) have an etha-
nolamine head group in common. To date, two main biosynthesis
pathways for PE are known. The Kennedy pathway generates PE de
novo and is crucial also for the ﬁnal steps of PlsEtn production [42].
Here, PE synthesis starts from ethanolamine, which becomes phosphor-
ylated and then activated by cytidine triphosphate (CTP). Cytidine
diphosphate (CDP)-ethanolamine subsequently reacts with diacylglyc-
erol completing the biosynthesis of PE [43]. Alternatively, PE can be pro-
duced via decarboxylation of PS at the inner mitochondrial membrane
[44,45]. The importance of both of these pathways is stressed by the
fact that targeted inactivation of either Pcyt2, the gene coding for the
rate-limiting enzyme of the Kennedy pathway, or Pisd, the gene coding
for PS decarboxylase, leads to embryonic death in mice [46,47]. Being
the secondmost abundant phospholipid in eukaryotic cells, PE is essen-
tial for both structure and function ofmembranes. It is usually located at
the cytoplasmic face ofmembranes,where, due to its cone shape, it sup-
ports the formation of non-lamellar structures. In addition, PE has been
found to stabilize membrane proteins and to assist in their folding [48].
In the present study, we investigated how the level and side chain
composition of PE respond to PlsEtn deﬁciency and to excess of PlsEtn in-
duced by exogenous supplementation with precursors. To this end, we
used ﬁbroblasts derived fromRCDP patients and graymatter brain tissue
of Gnpat knockout mice as in vitro and in vivomodels of ether lipid deﬁ-
ciency. The main objective was to determine how alterations in the
PlsEtn concentration affect: (i) the total level of ethanolamine phospho-
lipids (PE + PlsEtn); (ii) the total PUFA level; and (iii) the side chain
composition at the sn-2 position of ethanolamine phospholipids.
2. Materials and methods
2.1. Patient phenotype classiﬁcation
Clinical and biochemical phenotypes of patients, whose cells were
studied here, have been described previously [32,49,50]. Phenotype
severity classes were based on clinical features, red blood cell (RBC)
plasmalogen levels and plasmalogen synthesis in patient ﬁbroblasts
(Fig. 2A and Table 1). Patients were classiﬁed as either severe or inter-
mediate RCDP. Compared with severe RCDP, the intermediate form is
characterized by improved growth and development and may not
involve rhizomelia. In the intermediate form, residual plasmalogen syn-
thesis and RBC plasmalogen levels are at least 30% of the control mean
and more than two standard deviations above the severe RCDP mean.
2.2. Determination of plasmalogen biosynthesis rate and RBC plasmalogens
Plasmalogen biosynthesis rates and RBC plasmalogen levels were
determined by established methods in the Peroxisomal Diseases Labo-
ratory at the KennedyKrieger Institute [51–53]. Brieﬂy, for themeasure-
ment of plasmalogen biosynthesis, cultured cells were incubated with
Fig. 2. PlsEtn levels of cultured RCDP ﬁbroblasts correlate with disease severity.
(A) Plasmalogen biosynthesis rates were determined by the method of Roscher et al.
[51] and are depicted as ratio between the peroxisomal (14C) and the ER (3H) steps of bio-
synthesis. Typical biosynthesis rates of healthy controls are indicated by the shaded area
(“reference range”). ***P ≤ 0.001; **P ≤ 0.01 (one-sample t-test versus reference range;
two-tailed t-test comparing intermediate and severe RCDP ﬁbroblasts) (B) PlsEtn levels
were measured in primary human ﬁbroblasts. PlsEtn subspecies are grouped according
to their different sn-1 moieties indicated by 16:0, 18:0 and 18:1. Data are represented as
means ± SD derived from at least three different cell lines per group. ***P ≤ 0.001;
*P≤ 0.05 (one-wayANOVAwith Tukey's post hoc test for comparison of total plasmalogen
levels).
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separated by thin layer chromatography and the 14C/3H ratio in
plasmalogens determined. Incorporation of the 14C substrate requiresTable 1
Summary of primary human skin ﬁbroblasts derived from RCDP patients.
ID Disease severity RCDP type (mutated gene) Mutation
RCDP 1-1 Intermediate 1 (PEX7) H285R/L292
RCDP 1-2 Severe 1 (PEX7) H39P/W206
RCDP 1-3 Severe 1 (PEX7) L292X/L292X
RCDP 2-1 Intermediate 2 (GNPAT) c. 1937 + 5G
RCDP 2-2 Severe 2 (GNPAT) c. 1428delC/
RCDP 3-1 Intermediate 3 (AGPS) E471K/E471
RCDP 3-2 Severe 3 (AGPS) T568M/T568
a Reference values in controls: 0.065 ± 0.01; ratio of C16:0 dimethylacetals (representing pthe peroxisomewhile that of the tritiated substrate bypasses the perox-
isomal steps and requires ER reactions, thereby serving as an internal
control. Thus, the ratio of 14C to 3H incorporation into plasmalogens pro-
vides an accurate and reproducible measure of the peroxisomal ether
lipid biosynthesis steps.
To determine RBC plasmalogens, lipids were extracted from packed
RBCs derived from EDTA whole blood using isopropanol/hexane (2:3
vol/vol). The lipid layer was dried under a stream of nitrogen and ex-
posed to 1Mmethanolic HCl at 75 °C overnight to yield fatty acidmeth-
yl esters (FAME) from complex lipids and dimethylacetals (DMA) from
plasmalogens. FAME and DMA were extracted from acidic methanol
with hexane and analyzed by capillary gas chromatography. Both
were referred to internal standards and results presented as ratios
C16:0 DMA/C16:0 FAME.2.3. Cell culture
Mutated genes (determining the RCDP subtype) and mutations of
human primary RCDP skin ﬁbroblasts are summarized in Table 1. In-
formed consent for the use of patient cell lines for researchwas obtained
from the Johns Hopkins Hospital (Baltimore, USA) and the McGill
University Health Center according to institutional guidelines. Control
ﬁbroblasts derived frommetabolically healthy individuals were obtain-
ed from the General Hospital of Vienna (AKH). All studies involving
human ﬁbroblasts were approved by the Ethical Review Board of the
Medical University of Vienna (application no. 729/2010).
Fibroblasts were maintained at 37 °C and 5% CO2 in RPMI-1640
medium (Lonza) supplied with 10% fetal bovine serum (FBS) (PAA),
2mM L-glutamine (Lonza), 50 units/ml penicillin, 100 μg/ml streptomy-
cin (Invitrogen) and 0.5% fungizone (Invitrogen). For application of
plasmalogen precursors, ﬁbroblasts were supplemented with 20 μM
1-O-hexadecylglycerol (Alexis Biochemicals) or batyl alcohol (1-O-
octadecylglycerol, Sigma), each dissolved in ethanol, for three subse-
quent days with change of medium every 24 h.2.4. Mice
Mice with a targeted inactivation (knockout) of the Gnpat gene
(Gnpattm1Just) have been described previously [19]. The strainwasmain-
tained on an outbred C57BL/6 × CD1 background and experimental
cohorts with Gnpat−/− (ko) and Gnpat+/+ (wt) littermates were ob-
tained by mating heterozygous animals. Genotypes were determined
at weaning by PCR as described previously [19] and conﬁrmed after
sacriﬁce. Mice were fed standard chow with food and water ad libitum
andwere housed in a temperature- and humidity-controlled roomwith
12:12 h light–dark cycle and a low level of acoustic background noise at
the local animal facility of the Medical University of Vienna. All animals
received humane care and handling in compliance with the national
(Austrian) regulations (BGBl. II Nr. 522/2012) and the directive 2010/
63/EU of the European Parliament and the council of the European
Union.RBC plasmalogens in patient (C16:0)a Reference
X 0.031 [32]
X 0.002 [32]
0.001 [32,49]
NA/c. 1937 + 5GNA 0.060 [49]
c. 1428delC 0.005 [49,50]
K 0.028 [49]
M 0.003 [49]
lasmalogens) to C16:0 fatty acid methyl esters (representing other lipids).
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For homogenization of cultured cells, around 106 cells were
washed with sterile PBS and distilled water (dH2O) and subsequent-
ly scraped into 1 ml of dH2O. Homogenates were obtained by passing
through 23-G (2 passages), 25-G (2 passages) and 27-G (3 passages)
needles.
For homogenization of brain material, mice were sacriﬁced by CO2
inhalation and their brains removed. To obtain gray matter samples,
cerebral cortex and hippocampus were dissected and combined before
homogenizing in dH2O (100 mg tissue/ml) supplied with cOmplete™
protease inhibitor cocktail (Roche Applied Science) using a glass–Teﬂon
tissue grinder (Potter-Elvehjem homogenizer) at 4 °C. All homogenates
were stored in aliquots at -80 °C until further use.2.6. Determination of phospholipids
Lipid extractions were performed according to Bligh and Dyer [54].
Brieﬂy, to 500 μl aqueous sample in a 10 ml Wheaton vial with Teﬂon-
screw cap 3.75 vol of CHCl3/MeOH (5:10; vol/vol) were added and
vortexed for 5 min, followed by the stepwise addition of 500 μl CHCl3
and 500 μl H2O, with 5 min vortex mixing after each step. Samples
were centrifuged for 5 min at 500 × g to facilitate phase separation.
The lower organic phase was transferred with a glass pipette to a new
Wheaton vial containing 500 μl H2O, while the upper phase was re-
extracted with 500 μl CHCl3. After vortex mixing and centrifugation,
the lower phase of the vial, to which H2O was added, was transferred
to a new Wheaton vial, and the lower phase from the CHCl3 re-
extraction was transferred to the vial containing the residual H2O
phase. Following vortex mixing and centrifugation, the lower phase
was added to the lower phase from the ﬁrst H2O wash and the com-
bined CHCl3 phases were subjected to solvent evaporation under a gen-
tle nitrogen ﬂow at 37 °C. Lipid ﬁlms were resuspended in mass
spectrometry (MS) solvent or were directly used for phosphate deter-
minations [55].
For mass spectrometry, 4 nmol phospholipids per sample were ex-
tracted in the presence of a lipid standard mix containing 33 pmol
PlsEtn-Mix 1 (16:0p/15:0, 16:0p/19:0, 16:0p/25:0), 46.5 pmol PlsEtn-
Mix 2 (18:0p/15:0, 18:0p/19:0, 18:0p/25:0), 64.5 pmol PlsEtn-Mix 3
(18:1p/15:0, 18:1p/19:0, 18:1p/25:0), 100 pmol PC (26:0, 28:0, 40:0
and 42:0), 100 pmol SM (d18:1/14:0, d18:1/17:0 and d18:1/25:0),
50 pmol PE (28:2, 40:2 and 44:2) and 50 pmol PS (28:2, 40:2 and
44:2). PE and PS [56], PlsEtn [57] and SM [58] standards were synthe-
sized and puriﬁed via HPLC as described. PC standards were purchased
from Avanti Polar Lipids. Dried lipids were dissolved in 100–200 μl
methanol containing 10 mM ammonium acetate. Mass spectrometric
analyses were done on a triple quadrupole instrument (Quattro II,
Micromass) equipped with a nano-electrospray ionization (ESI) source.
Nano ﬂow tips were purchased from Teer Coatings. The source temper-
ature was set to 30 °C and a capillary voltage of±600–900 V and a cone
voltage of 30 V were applied, depending on the ion mode. Argon was
used as collision gas at a nominal pressure of 2.5 × 10−3 mbar. PC and
SM species were analyzed by precursor ion scanning in positive ion
mode, selecting for fragment ions of 184 Da (collision energy of
32 eV). PlsEtn quantitation was performed by precursor ion scanning
in positive ion mode, selecting for fragment ions of 364 Da (16:0p
species), 390Da (18:1p species), and 392Da (18:0p species),with a col-
lision energy of 18–20 eV. PS and PE species were detected by neutral
loss scanning, selecting for a neutral loss of 141 Da or 185 Da (positive
ion mode), respectively, with a collision energy of 20 eV. Peak lists
were corrected for C13 isotope effects and for mass-dependent changes
in the response as described [59]. Lipid data are presented as mole% of
measured phospholipids. Lipid species were annotated as follows:
lipid category_ total number of C-atoms in the fatty acyl chains:number
of double bonds.2.7. Data analysis and statistical testing
A summary of all measured phospholipid species is provided in Sup-
plementary Table 1. The following species were added to the group of
PUFA-containing PE: 36:5, 36:4, 36:3, 38:6, 38:5, 38:4, 38:3, 40:7,
40:6, 40:5, 40:4, 40:3. PE 36:2 and 38:2 were not included, as, at least
in mouse cerebellum, these species were found to almost exclusively
consist of monounsaturated fatty acid chains [60]. Furthermore, both
representminor species and their inclusionwould not cause any notice-
able change in the amount of PUFA-containing PE. In order to estimate
the amounts of arachidonic acid (AA) and docosahexaenoic acid
(DHA) in PE, subspecies were grouped according to the number of dou-
ble bonds in their side chains at the sn-1 and sn-2 position. In agreement
with recent literature, we assumed that species with four or ﬁve double
bonds usually contain AA, whereas species with six or seven double
bonds usually involve a DHA side chain [60].
In general, all phospholipid determinations involving cultured cells
were done in triplicates (three samples per cell line). The means of
these triplicates were used to form the groups of control, intermediate
RCDP and severe RCDP ﬁbroblasts. All error bars in the graphs reﬂect
standard deviations. Statistical analysis was performed using Sigma
Plot 12.0 (Systat Software) and PASW Statistics 18.0 (SPSS Inc.).
Plasmalogen biosynthesis rates of intermediate and severe RCDP ﬁbro-
blasts were compared with each other by two-tailed t-test and with
the reference range by one-sample t-tests. Results involving control,
intermediate and severe RCDP ﬁbroblasts were statistically evaluated
by one-way analysis of variance (ANOVA) with Tukey's post hoc test.
Where linear trends between the three groups were examined,
unweighted linear terms were calculated in the course of one-way
ANOVA. Also, planned contrasts (one-tailed) were used to compare
controls with both RCDP groups in terms of fatty acid species in PE. In
case of treatment experiments, statistical analysis was done by one-
way ANOVA with Dunnett's post hoc test using ethanol-treated control
cells as reference. Results involving wild type and Gnpat knockout mice
were analyzed by two-tailed t-tests.
P values derived from post-hoc testing after ANOVA and from t-tests
were adjusted for multiple testing in case of control lipid classes (PC,
SM, PS) and fatty acid species at the sn-2 position of plasmalogens
using Bonferroni–Holm correction.
3. Results
3.1. Disease severity is reﬂected by the amount of PlsEtn in primary
ﬁbroblasts of RCDP patients
In order to assess changes in the lipid proﬁle as a consequence of
plasmalogen deﬁciency, we quantiﬁed different lipid species in primary
skin ﬁbroblasts derived from RCDP patients and, for comparison, from
healthy controls using nano-mass spectrometry (Supplementary
Table 1). Patient ﬁbroblasts represented all three types of RCDP, includ-
ing three cell lines of RCDP type 1 and two lines each of RCDP type 2 and
type 3 (Table 1). First, we compared plasmalogen biosynthesis rates of
the different ﬁbroblasts. To this end, cultured cells were supplied with
radiolabeled hexadecanol (14C) and hexadecylglycerol (3H), which are
both metabolized to plasmalogens. Whereas hexadecanol depends on
peroxisomes to be incorporated into plasmalogens, hexadecylglycerol
bypasses the peroxisomal steps and plasmalogen biosynthesis fully
proceeds at the ER. Consequently, the incorporation ratio of the two
labels can be used as a measure of the peroxisomal contribution to
plasmalogen biosynthesis activity. Independent of the type of RCDP,
which is deﬁned by the genotype, biosynthesis rates were in good
agreement with the clinical disease severity of the respective patients.
When the RCDP lines were grouped according to the course of the
disease, the activity ratios differed strongly from each other. Cells
from patients with intermediate RCDP showed clearly impaired
plasmalogen biosynthesis compared with controls, whereas in cells
Fig. 3. Total ethanolamine phospholipid levels are precisely maintained upon PlsEtn deﬁ-
ciency. (A) The levels of the main phospholipid classes were determined in primary
human ﬁbroblasts derived from healthy controls, intermediately and severely affected
RCDP patients bymass spectrometry. Data representmeans±SDof at least three different
cell lines per group. ***P ≤ 0.001; *P ≤ 0.05 (one-way ANOVA with Tukey's post hoc test;
Bonferroni–Holm correction formultiple testing in control lipid classes) (B) Total ethanol-
amine phospholipid levels are depicted as stacked bars composed of PlsEtn and PE levels.
Data consist ofmean values for the two lipids as shown inA. P≥ 0.60 for all comparisons of
total ethanolamine phospholipid levels (one-way ANOVA with Tukey's post hoc test). PE,
phosphatidylethanolamine; PlsEtn, ethanolamine plasmalogen; PC, phosphatidylcholine;
SM, sphingomyelin; PS, phosphatidylserine.
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be detected (Fig. 2A). Accordingly, for further analyses, the RCDP ﬁbro-
blast lines were classiﬁed into intermediate (n= 3) and severe (n= 4)
cases.
Next, we performed a quantiﬁcation of PlsEtn levels using nano-
electrospray ionization tandem mass spectrometry (nano-ESI–MS/
MS), which revealed that the severity of disease in RCDP patients was
also reﬂected by the residual amount of PlsEtn in the cultured ﬁbro-
blasts. Comparedwith control lines, ﬁbroblasts of the intermediately af-
fected group were found to have about 40% reduced levels of PlsEtn,
while those derived from patients with severe phenotype displayed a
more pronounced reduction ofmore than 70% representing a highly sig-
niﬁcant linear trend between the three examined groups (P b 0.001).
This decrease affected all plasmalogen subtypes, irrespective of
their sn-1 chain (Fig. 2B). C16:0 turned out to be the most abundant
species in controls as well as in both RCDP groups. Compared with
the intermediate RCDP group, the residual PlsEtn in ﬁbroblasts of
severely affected patients was more strongly depleted in C18:0
than in the two other species (Fig. 2B). Furthermore, PlsEtn levels
of cultured ﬁbroblasts clearly correlated with those in red blood
cells of the corresponding patients (Table 1). Although plasmalogen
levels in patient ﬁbroblasts were in accordance with their rate of
biosynthesis, there was an unexpected residual amount of PlsEtn in
ﬁbroblasts of the severely affected group. Residual plasmalogens in
different types of cultured ether phospholipid-deﬁcient cells were also
reported by others [61–63]. Furthermore,wemade similar observations
in embryonic ﬁbroblasts derived from Gnpat knockout mice (data not
shown), in which plasmalogens are virtually absent in vivo [19]. There-
fore, residual plasmalogens – or their precursors – most likely are
derived from the serum added to the culture medium. Attempts to
avoid this uptake by the use of synthetic medium without serum were
unsuccessful due to reduced viability and a general change in the phos-
pholipid proﬁle (data not shown). Thus, we retained our original cul-
ture conditions to allow for comparison of our results with previous
studies.
3.2. PE strictly compensates for plasmalogen deﬁciency
In order to investigate compensatory alterations of the lipid proﬁle
in response to decreased plasmalogen levels, we analyzed the main
phospholipid classes in control and RCDP ﬁbroblasts. In particular, we
were interested in how different degrees of plasmalogen reduction
affect potential compensatory mechanisms. Consistent with previous
reports in other cell types or tissues [19,64–67], the reduction of PlsEtn
in RCDP ﬁbroblasts was accompanied by a rise in PE. All other major
classes of phospholipids, including PC, SM and PS, remained at the
level of controls (Fig. 3A). PE levels adapted conversely to the degree
of plasmalogen deﬁciency, keeping the total amount of ethanolamine-
containing phospholipids remarkably constant, slightly below 30% of
total phospholipids (Fig. 3B). While in controls almost half of all etha-
nolamine phospholipids was PlsEtn, PE accounted for almost 75% and
90% of ethanolamine species in the ﬁbroblasts of intermediately and se-
verely affected patients, respectively. The continuous increase of PE over
the three groups was also reﬂected statistically by a highly signiﬁcant
linear trend (P b 0.001).
3.3. Compensation for plasmalogen deﬁciency is mainly accomplished
through arachidonic acid-containing, but not docosahexaenoic acid-
containing PE species in human ﬁbroblasts
Both PlsEtn and PE are rich in PUFAs; among these, arachidonic acid
(AA, C20:4ω-6) and docosahexaenoic acid (DHA, C22:6ω-3) are the
most abundant. In order to investigate if the total amount of PUFAs
and also the ratio between AA and DHA are maintained upon compen-
sation of plasmalogen deﬁciency by PE, we analyzed the fatty acid com-
position of PlsEtn and PE in control and RCDP ﬁbroblasts. At the sn-2position of PlsEtn, the major difference between the ﬁbroblast groups
was an increased frequency of AA (though not statistically signiﬁcant)
replacing C22:5 and C22:4 in both RCDP ﬁbroblast groups compared
with controls (Fig. 4A and Supp. Fig. 1). Interestingly, both latter species
changed in a similar way and magnitude, and a clear linear trend from
controls to severe RCDP ﬁbroblasts was observed (P= 0.001 for C22:5
and P = 0.003 for C22:4). Whereas C22:4 is normally exclusively of
the ω-6 type, C22:5 can be either ω-3 (serving as a precursor for
DHA) or ω-6 (derived from the metabolization of C22:4) [68,69]. As
C22:4 (ω-6) levels were found to be lowered in RCDP ﬁbroblasts,
whereas DHA (ω-3) remained unchanged, it is tempting to speculate
that the reduced occurrence of C22:5 ismainly attributable to a decrease
in the ω-6 component. The abundance of AA at the expense of C22:5
and C22:4 seems unlikely to be due to plasmalogens or their precursors
present in the culture medium, as it was not restricted to the severely
affected ﬁbroblasts, but also found in cells of patients with intermediate
disease course, where residual plasmalogen biosynthesis contributes to
the PlsEtn content.
Fig. 4. Ethanolamine phospholipids of RCDP ﬁbroblasts have normal levels of total PUFAs
but are enriched in arachidonic acid. (A) The composition of the sn-2 side chainswas deter-
mined in PlsEtn of the different ﬁbroblast groups and the concentrations of the individual
species were calculated as percentage of total PlsEtn. To enable better comparison, relative
values for themost abundant species are shownwith those of the control group normalized
to 100%. Values not normalized to controls for all measured species are shown in Supp.
Fig. 1. *P≤ 0.05 (one-way ANOVA with Tukey's post hoc test; Bonferroni–Holm correction
for multiple testing) (B) PUFA side chains were added up in PlsEtn and PE. Horizontal lines
in the bars representing total PUFA species indicate the different contributions of PE and
PlsEtn. Individual species contributing to the PUFA group are listed in Section 2.7. ***P ≤
0.001; *P ≤ 0.05; n.s., not signiﬁcant (one-way ANOVA with Tukey's post hoc test).
P ≥ 0.98 for all comparisons of total PUFA levels (C) PE species were grouped according
to the number of double bonds in their side chains into PE with 4–5 double bonds (mostly
AA-containing) or PE with 6–7 double bonds (mostly DHA-containing). Data represent
means± SD of at least three different cell lines. ***P≤ 0.001; *P≤ 0.05; n.s., not signiﬁcant
(one-way ANOVA with Tukey's post hoc test).
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amine phospholipids (PE and PlsEtn), we found that compensation for
plasmalogen deﬁciencywas also reﬂected in the levels of these essential
fatty acids. The total amount of PUFAs incorporated into ethanolamine
phospholipids was equal in controls and ﬁbroblasts of patients with
intermediate and severe RCDP (Fig. 4B), indicating a strict adaptation
of the ﬁbroblasts to the condition of ether phospholipid deﬁciency
also in terms of PUFA side chains. This ﬁnding is underlined by the
observed linear trends for the amounts of PUFAs in both phospholipid
species: a decreasing one in PlsEtn (P b 0.001) and an increasing one
in PE (P b 0.001).
Subsequently, we investigated whether PE species containing the
twomain PUFAs, AA andDHA, increase to a similar extent in RCDP ﬁbro-
blasts. Because our mode of analysis of PE produced the sum of both
fatty acid chains (e.g. 38:4), we grouped the PE species into those
containing 4–5 and 6–7 double bonds. According to recent lipidomic
studies, the former predominantly contain AA and the latter DHA [60].
Our analysis revealed that PlsEtn deﬁciency was almost exclusively
compensated for by PE containing fatty acids with a total of 4–5 double
bonds (AA-containing). Compared with controls, these species were al-
most doubled in concentration in both of the RCDP ﬁbroblast groups. In
contrast, the proportion of PE containing fatty acids with 6–7 double
bonds (DHA-containing) was not altered in intermediately affected
RCDP ﬁbroblasts and only slightly increased in severely affected cells
(Fig. 4C). A comparison of controls with both RCDP groups revealed a
highly signiﬁcant difference in the species with 4–5 double bonds
(P=0.005 using planned contrasts), but not in species with 6–7 double
bonds (P=0.097). In total, these results indicate that compensatory re-
sponses to plasmalogen deﬁciency predominantly involve AA, but not
DHA, thus leading to a remarkable shift in the ratio between these
two essential PUFAs.3.4. PE levels in plasmalogen-deﬁcient ﬁbroblasts dynamically adapt to
exogenous precursor supplementation
Deﬁciency in plasmalogen biosynthesis can be overcome in vitro and
in vivo, with the exception of the brain, by dietary application of precur-
sor substances that circumvent the peroxisomal biosynthesis steps [70,
71]. In order to investigate their lipid composition under conditions of
excess of plasmalogens, we treated RCDP (RCDP 1–3, cf. Table 1) and
control ﬁbroblasts with the ether phospholipid precursors batyl alcohol
(BA; octadecylglycerol) or hexadecylglycerol (HDG), which are O-
alkylglycerols with an ether-bonded C18:0 and C16:0 chain, respective-
ly, at the sn-1 position. After three days of plasmalogen precursor treat-
ment, the levels of PlsEtn were restored also in severely affected RCDP
cells and even signiﬁcantly exceeded the control values reaching 1.5
times (BA) or even twice (HDG) the amounts of untreated control
cells. A similar rise in PlsEtn was also observed in treated controls
(Fig. 5A). As expected and in line with previous studies involving
plasmalogen precursor treatment [7,72,73], we did not ﬁnd any side
chain remodeling at the sn-1 position. As a consequence, only one of
the three main PlsEtn species was rescued by the supplementation
with BA or HDG, namely the C18:0 and C16:0 species, respectively.
The two other species (C16:0, C18:1 and C18:0, C18:1 in case of BA
and HDG treatment, respectively) remained at very low levels in the
treated RCDP ﬁbroblasts (Fig. 5A).
We also examined the overall phospholipid proﬁle of the ﬁbroblasts
upon PlsEtn restoration by precursor supplementation. Consistent with
the above ﬁndings in ﬁbroblasts of RCDP patients with severe and inter-
mediate disease course (Fig. 3), both BA and HDG supplementation had
a strong effect on PE levels, whereas the levels of the other main phos-
pholipid classes remained grossly unchanged, except for a small reduc-
tion in the levels of PC seen after HDG treatment in controls (P b 0.001)
and also, by trend, in RCDP ﬁbroblasts (P = 0.052 after adjustment
for multiple testing; Supp. Fig. 2). Similar to under conditions of
Fig. 5. PE levels drop in response to excessive plasmalogen levels. (A) A control ﬁbroblast line and a line derived from an RCDP patient with severe disease course were left untreated or
were treatedwith solvent (ethanol, EtOH) orwith plasmalogen precursor substances (BA, batyl alcohol; HDG, hexadecylglycerol). PlsEtn levelswere determined and displayed according
to their different sn-1moieties (16:0, 18:1 and 18:0). Data are shown asmeans±SDof three independent experiments. ***P≤ 0.001; **P≤ 0.01; n.s., not signiﬁcant (one-wayANOVAwith
Dunnett's post hoc test) (B) Total ethanolamine phospholipid levels of untreated, solvent-treated and plasmalogen precursor-treated ﬁbroblasts are depicted as stacked bars composed of
PlsEtn and PE levels. Data consist of mean values for the two lipids as shown in A. P≥ 0.16 for all comparisons of total ethanolamine phospholipid levels (one-way ANOVAwith Dunnett's
post hoc test).
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of PE levels inversely proportional to the amount of PlsEtn. Total etha-
nolamine phospholipid homeostasis was maintained with PlsEtn
constituting the major portion and PE accounting for only 17–30% of
total ethanolamine species (Fig. 5B).
Both BA and HDG have been suggested for the treatment of human
ether phospholipid deﬁciency [21,71,74,75]. When evaluating their po-
tency, it is crucial to consider the restoration of both plasmalogen levels
and the broad range of sn-2-positioned PUFAs. Therefore, we also deter-
mined the total amount of PUFAs in both ethanolamine phospholipid
species. In controls as well as in RCDP ﬁbroblasts, precursor-treated
and untreated, the level of PUFAs was kept constant (Fig. 6) indicating
that, independent of the type of ethanolamine phospholipid, PUFAs
are incorporated in strictly maintained amounts. Moreover, the distri-
bution of individual fatty acid species at the sn-2 position after treat-
ment was nearly identical to that in control ﬁbroblasts (data not
shown).3.5. PE of murine gray matter tissue similarly adapts to plasmalogen
deﬁciency
The Gnpat knockout mouse, in which the ﬁrst enzyme in the ether
lipid biosynthesis pathway is inactivated, serves as a model of RCDP
[19]. As a consequence of their inability to synthesize ether lipids,
these animals show symptoms reminiscent of RCDP like growth and
mental retardation, defective myelination, visual impairments, infertili-
ty and a reduced lifespan [19,76,77]. In human graymatter of the brain,
more than 50% of ethanolamine phospholipids are present as
plasmalogens [37]; therefore, we analyzed the extent of compensation
for PlsEtn deﬁciency in vivo in cerebral gray matter of Gnpat knockout
mice. As expected, PlsEtn was hardly detected in the tissue of Gnpat
knockout mice, whereas in wild type gray matter it accounted for
almost 50% of ethanolamine phospholipids, corresponding to about
20% of total phospholipids. C18:0 was the most prevalent sn-1 species,
followed by C18:1 and C16:0 (Supp. Fig. 3). Complete PlsEtn deﬁciency
Fig. 6. The total amount of PUFAs in ethanolamine phospholipids is maintained regardless of plasmalogen precursor status. The total amounts of PUFA side chains in PlsEtn and PE of
untreated, solvent-treated or plasmalogen precursor-treated ﬁbroblasts were determined. Horizontal lines in the bars representing total PUFA species indicate the different contributions
of PE and PlsEtn. Individual species contributing to the PUFA group are listed in Section 2.7. Data represent means ± SD of at least three different cell lines. ***P≤ 0.001; **P≤ 0.01; *P≤
0.05; n.s., not signiﬁcant; n.t., not tested (one-way ANOVA with Dunnett's post hoc test). P ≥ 0.71 for all comparisons of total PUFA levels. BA, batyl alcohol; HDG, hexadecylglycerol.
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Gnpat knockout mice amounted to the sum of ethanolamine phospho-
lipids (PlsEtn+PE) inwild type controls (Fig. 7A). These results strong-
ly conﬁrm our in vitro ﬁndings indicating that similar homeostatic
mechanisms maintain total ethanolamine phospholipid levels also
in vivo. As in RCDP ﬁbroblasts, in the murine brain PE was by far the
phospholipid contributing the most to the compensatory adaptation,
while other main lipid classes basically remained unchanged except
for a minor, but statistically signiﬁcant elevation of SM levels in Gnpat
knockout mice (Fig. 7B).
To evaluate the compensatorymechanism in greater detail, we again
focused on the sn-2 position of both ethanolamine phospholipids. Like
in human ﬁbroblasts, also in murine gray matter, PUFAs in PE compen-
sated for the lack of PUFAs in PlsEtn, leading to almost identical total
PUFA amounts in ethanolamine phospholipids in ether lipid-deﬁcient
and wild type brain tissue (Fig. 8A). Although in wild type PlsEtn (and
also PE) DHA was much more common than AA, compensatory upreg-
ulation was mainly restricted to predominantly AA-containing PE with
4–5 double bonds (Fig. 8B). These species increased from 8% of all mea-
sured phospholipids inwild type brains to 21% in the brains of knockout
animals, whereas there was only a minimal increase in mostly DHA-
containing PEwith 6–7 double bonds. Remarkably, although this causes
a massive change in the ratio between DHA and AA, there was no
counteracting enrichment of DHA in any other main phospholipid
class (data not shown).
Together with the results obtained in human ﬁbroblasts, these data
show that under conditions of plasmalogen deﬁciency, AA-containing
ethanolamine phospholipids are strongly elevated at the expense of
DHA-containing ethanolamine species. Thus, plasmalogen deﬁciency
results in an altered ratio of ω-6 and ω-3 fatty acids.
4. Discussion
Plasmalogens are major essential constituents of all cellular mem-
branes in mammals. Therefore, it appears evident that cells employ
compensatory mechanisms to maintain an optimal phospholipid com-
position in order to cope with plasmalogen deﬁciency. In the present
study, we found that the main compensatory response to the lack ofPlsEtn is an upregulation of PE. Previous studies have reported a rise
in PE levels as a consequence of plasmalogen deﬁciency [19,64–67].
Here, we extend this observation and show that the amounts of total
ethanolamine phospholipids are accurately regulated and sustained at
a remarkably constant level under conditions of complete or partial
absence aswell as upon excess of plasmalogens in vitro and in vivo. Dy-
namic adaptation of cellular phospholipid composition to exogenous
lipid alterations has previously been shown in other model systems,
for example, PC and PE adapt to changes inmembrane cholesterol levels
[78,79]. Here, we show that PE, but not the other major membrane
phospholipids, underlies a tight inverse adjustment in response to the
altered levels of PlsEtn.
Based on our results, the question arises, how such an accurate reg-
ulation of total ethanolamine phospholipids is accomplished. Two
major different pathways contribute to PE biosynthesis, which both
could potentially be involved in the homeostatic regulation of PE. The
ﬁrst, the Kennedy pathway, appears as an obvious candidate, as the
two ethanolamine phospholipid species share some steps of this bio-
synthesis pathway [42]. The production of both PE and PlsEtn depends
on ethanolaminephosphotransferase (EC 2.7.8.1) for the coupling of
CDP-ethanolamine to either diacylglycerol or alkylacylglycerol in the
last step of the pathway. Under most physiological conditions, the
generation of either CDP-ethanolamine or the lipid precursor is rate-
limiting [80]. If the compensatory increase (upon PlsEtn deﬁciency)
and decrease (upon ether lipid precursor supplementation) of PE
derives from the Kennedy pathway, we would assume that adaptation
results from the shift in the relative abundance of the two lipid precur-
sors, diacylglycerol and alkylacylglycerol, while CDP-ethanolamine
levels remain constant. Consequently, PE would be produced instead
of PlsEtn in the case of alkylacylglycerol depletion and, conversely,
under excess of alkylacylglycerol (as seen after plasmalogen precursor
treatment), PlsEtn levels would increase at the expense of PE. Thus,
our data are in good agreement with a regulation of total ethanolamine
phospholipids by adjusting the concentration of CDP-ethanolamine
generated by CTP:phosphoethanolamine cytidyltransferase (ECT, EC
2.7.7.14). In humans, this enzyme is encoded by the PCYT2 gene. Knowl-
edge about if and how ECT is regulated by phospholipid levels is limited,
but recent studies in various cell lines showed transcriptional
Fig. 7. Total ethanolamine phospholipid levels are maintained also in the plasmalogen-
deﬁcient murine brain. Gray matter tissue (cerebral cortex and hippocampus) was dis-
sected fromwild type (wt, n = 10) and Gnpat knockout (ko, n = 4) mice for quantitative
analysis of the main phospholipid classes. (A) Total ethanolamine phospholipid levels are
depicted as stacked bars composed of mean values of the PlsEtn and PE levels. P= 0.227
(two-tailed t-test) (B) The levels of all major phospholipid classes are shown as means ±
SD of all mice examined. ***P ≤ 0.001 (two-tailed t-test; Bonferroni–Holm correction for
multiple testing in control lipid classes). PE, phosphatidylethanolamine; PlsEtn, ethanol-
amine plasmalogen; PC, phosphatidylcholine; SM, sphingomyelin; PS, phosphatidylserine.
Fig. 8.PUFA side chain analysis inmouse tissue conﬁrms that AA is enriched at the expense
of DHA in plasmalogen deﬁciency also in vivo. (A) PUFA side chains were added up in
PlsEtn and PE derived from wild type and Gnpat knockout (ko) gray matter tissue. Hori-
zontal lines in the bars representing total PUFA species indicate the different contributions
of PE and PlsEtn. Individual species contributing to the PUFA group are listed in Section 2.7.
***P ≤ 0.001 (two-tailed t-test) (B) PlsEtn species were grouped into AA-containing and
DHA-containing types, whereas PE species were grouped into such with 4–5 double
bonds (mostly AA-containing) or such with 6–7 double bonds (mostly DHA-containing).
Data represent means ± SD of 10 (wt) and 4 (Gnpat ko) animals per group. ***P ≤
0.001; **P ≤ 0.01 (two-tailed t-test). DB, double bonds.
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that is a deprivation of lipids [81,82]. For the second possibility, it has
been reported that, in cultured cells, PE biosynthesis is mainly depen-
dent on PS decarboxylation [43,80]. This pathway, however, supposedly
does not contribute to PlsEtn biosynthesis [42]. PE produced by PS de-
carboxylation differs from PE originating from the Kennedy pathway
in that it contains a larger proportion of PUFAs [83]. Our ﬁndings that
PUFA-rich PE compensates for plasmalogen deﬁciency, thus, are consis-
tent with an involvement of PS decarboxylase. Unfortunately, very little
is known about the regulation of PS decarboxylase activity. The possible
existence of a feedback loop, which is controlled by total ethanolamine
phospholipid levels, remains to be investigated. Currently, we can also
not exclude that reduced degradation or turnover of PE contributes to
the compensatory elevation.
Amajor function attributed to plasmalogens, especially in the central
nervous system, is the storage of PUFAs [11,84]. In the present study we
show that, even upon plasmalogen deﬁciency, the total amount of
PUFAs in ethanolamine phospholipids is kept constant in human ﬁbro-
blasts and in the murine brain. This is particularly intriguing since gray
matter plasmalogens are speciﬁcally enriched in PUFAs. The mainte-
nance of total PUFA levels is achieved by elevated levels of PE rich inPUFAs. A similar observation has beenmade in postmortembrain tissue
of a case with Zellweger syndrome, where PUFA-containing PE proved
to be increased [66]. However, in our models, the two major PUFA
species, DHA and AA, appear to be unequally represented in the altered
ethanolamine phospholipid fraction, pointing toward a selective
enrichment of AA over DHA in response to plasmalogen deﬁciency.
This observation is underlined by two ﬁndings: (i) residual PlsEtn in
RCDP ﬁbroblasts showed a trend toward increased proportions of AA
at its sn-2 position; and (ii) in comparison to control ﬁbroblasts or
wild type brains, AA-containing PE species were strongly elevated in
RCDP ﬁbroblasts as well as in gray matter from Gnpat knockout brains,
while DHA-containing PE largely remained the same. As a consequence,
our results offer a plausible explanation for the previously observed
general reduction of DHA in whole brain homogenates of Gnpat knock-
outmice [19]. Also in the brains of patients with peroxisome biogenesis
disorders (Zellweger spectrum), a decrease in DHA in ethanolamine
phospholipids was determined [85]. However, when comparing tissue
or ﬁbroblast levels of DHA of RCDP and Zellweger spectrum cases, it
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are affected, including the generation of DHA from its precursor [86]. In
addition, the increased amount of AA that we describe here, is in good
agreement with a recent study in a plasmalogen-deﬁcient murinemac-
rophage cell line demonstrating the enhanced release of PE-bound AA
upon stimulation [87].
All these observations raise the question as to the origin of the
observed changes. We suggest two alternative possibilities; the enrich-
ment of AA at the expense of DHA can be caused by either: (i) a differ-
ence in the availability of the two fatty acids; or (ii) a fortuitously or
deliberately altered regulation under conditions of plasmalogen deﬁ-
ciency. Concerning the ﬁrst alternative, it iswidely accepted that the ex-
ogenous supply and the availability of fatty acids are reﬂected by the
fatty acid composition of phospholipids [88,89]. However, in contrast
to Zellweger spectrum disorders, it is not obvious, why fatty acid avail-
ability would be altered in case of isolated ether lipid deﬁciency. In the
cultured cells, exogenous fatty acids are exclusively derived from the
medium and AA might be enriched compared with DHA, as it is also
the main fatty acid species in PE under healthy conditions (Fig. 4C).
This does not hold true for the murine gray matter, where DHA domi-
nates in wild type mice. In this case, PUFAs incorporated into PE could
be derived from the circulation [89] and, therefore, the fatty acid com-
position of PE in the brainmay reﬂect their availability in the periphery.
This view is supported by the fact that in blood cells, PE is richer in AA
than in DHA [90]. In the second possibility, the preferred integration
of AA could result from an altered regulation caused by ether lipid deﬁ-
ciency, for example, in the production of diacylglycerol. It is also possi-
ble that AA serves a speciﬁc function in the absence of plasmalogens,
such as providing distinct membrane properties or mediating signaling
tasks. Irrespective of the underlying mechanism, plasmalogen deﬁcien-
cy appears to affect cellular functions by shifting the ratio betweenω-6
(AA) and ω-3 (DHA) PUFAs.
In addition to the implications for the various inherited diseases asso-
ciated with complete or partial plasmalogen deﬁciency, such as RCDP or
Zellweger spectrum disorders, our ﬁndings may be of relevance also for
more common disorders with less severe plasmalogen deﬁcits, like
Alzheimer's disease [36–38]. On the one hand, we show that deﬁciency
of PlsEtn is rigorously counterbalanced by the rise in PE, implying that
symptoms associated with these diseases are not the result of a general
shortage of ethanolamine phospholipids. On the other hand, our results
indicate that impaired biosynthesis of ether phospholipids precipitates
a dual deﬁcit, which is not compensated for by PE. One problem is the
absence of phospholipids harboring the ether bond; the other is the
decrease in DHA and the resulting dysbalance of ω-6 and ω-3 PUFAs. It
is tempting to speculate about which phenotypic consequences derive
from which deﬁcit. The characteristic vinyl ether linkage attributes ex-
traordinary biophysical properties to plasmalogens, for example by con-
ferringmembrane compaction and favoringmembrane fusion [15,16,91].
Accordingly, impairments of membrane structure result from the deﬁ-
ciency of the ethermoiety, even if ether lipids are replaced by their diacyl
counterparts. Membrane compaction, for example, is a prerequisite in
brain white matter myelin sheaths, which are affected by de- and
dysmyelination in RCDP [92] or ether lipid-deﬁcient mouse models [77].
Potentially, the vinyl ether bondhas been suggested to exert antioxidative
functions [15,67,93], which might be impaired by a reduced amount of
plasmalogens, thus, inducing or aggravating oxidative stress. DHA, in
turn, is known to be crucial for a variety of metabolic and immunologic
processes [94]. In general, ω-6 and ω-3 fatty acids are metabolized to a
large number of different immune mediators that serve pro- as well as
anti-inﬂammatory functions [95]. As these two types of fatty acids cannot
be mutually converted into each other, homeostasis of immunologic
reactivity requires a constant ratio of ω-6/ω-3 PUFAs. As highlighted
in a variety of nutritional studies, the permanent shift of this ratio to-
ward ω-6 fatty acids is unfavorable and has been shown to be associat-
edwith cardiovascular disease or the development of inﬂammatory and
neurodegenerative disorders, including Alzheimer's disease [96–98].In conclusion, the present ﬁndings reveal extensive compensatory
adaptations in the phospholipid composition, mainly in PE, in response
to disturbances in PlsEtn metabolism. However, these homeostatic
processes lead to a shift in the ratio of ω-6/ω-3 PUFAs. Thus, our study
emphasizes the complexity of lipid homeostasis and the necessity to
carefully consider these intricate compensatory mechanisms when
dealing with possible consequences of plasmalogen depletion, or
altered phospholipid composition in general, for different diseases and
treatment strategies.
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